Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein
- 2 January 2015
- journal article
- research article
- Published by Taylor & Francis Ltd in mAbs
- Vol. 7 (1), 265-275
- https://doi.org/10.4161/19420862.2014.985021
Abstract
Monoclonal antibodies (mAbs) play an increasing important role in the therapeutic armamentarium against multiple sclerosis (MS), an inflammatory and degenerative disorder of the central nervous system. Most of the mAbs currently developed for MS are immunomodulators blocking the inflammatory immune process. In contrast with mAbs targeting immune function, GNbAC1, a humanized IgG4 mAb, targets the multiple sclerosis associated retrovirus envelope (MSRV-Env) protein, an upstream factor in the pathophysiology of MS. MSRV-Env protein is of endogenous retroviral origin, expressed in MS brain lesions, and it is pro-inflammatory and toxic to the remyelination process, by preventing the differentiation of oligodendrocyte precursor cells. We present the preclinical and early clinical development results of GNbAC1. The specificity of GNbAC1 for its endogenous retroviral target is described. Efficacy of different mAb versions of GNbAC1 were assessed in MSRV-Env induced experimental allergic encephalitis (EAE), an animal model of MS. Because the target MSRV-Env is not expressed in animals, no relevant animal model exists for a proper in vivo toxicological program. An off-target 2-week toxicity study in mice was thus performed, and it showed an absence of safety risk. Additional in vitro analyses showed an absence of complement or antibody-dependent cytotoxicity as well as a low level of cross-reactivity to human tissues. The first-in-man clinical study in 33 healthy subjects and a long-term clinical study in 10 MS patients showed that GNbAC1 is well tolerated in humans without induction of immunogenicity and that it induces a pharmacodynamic response on MSRV biomarkers. These initial results suggest that the mAb GNbAC1 could be a safe long-term treatment for patients with MS with a unique therapeutic mechanism of action.Keywords
This publication has 33 references indexed in Scilit:
- GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical StudyClinical Therapeutics, 2012
- Expression and Activation by Epstein Barr Virus of Human Endogenous Retroviruses-W in Blood Cells and Astrocytes: Inference for Multiple SclerosisPLOS ONE, 2012
- Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis diseaseMultiple Sclerosis Journal, 2012
- Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral originNucleic Acids Research, 2011
- Managing the risks of immunosuppressionCurrent Opinion in Neurology, 2011
- Monoclonal antibody therapy in multiple sclerosismAbs, 2010
- Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosisMultiple Sclerosis Journal, 2010
- Lack of immune responses against multiple sclerosis–associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosisJournal of NeuroVirology, 2008
- Multiple sclerosis: a complicated picture of autoimmunityNature Immunology, 2007
- Phylogeny of a Novel Family of Human Endogenous Retrovirus Sequences, HERV-W, in Humans and Other PrimatesAIDS Research and Human Retroviruses, 1999